Clinical trial failure insurance is turning biotech’s most costly risk into a manageable asset, opening new pathways for funding and innovation.

Managing Director at NFP ...

Clinical trial failure insurance is turning biotech’s most costly risk into a manageable asset, opening new pathways for funding and innovation.

The FDA’s green light for a Phase II trial (JSKN003-202) of JSKN003 accelerates efforts to address platinum-resistant ovarian ...

Results from the long-term extension of the Phase III TRAILBLAZER-ALZ 2 trial (NCT04437511) showed sustained benefits with ...

New statistical frameworks such as net treatment benefit offer a multidimensional approach to evaluating efficacy, safety, ...

In this pilot episode of the Applied Clinical Trials Brief, we examine the renewed push for placebo-controlled vaccine trials ...

In this video interview, Michael Miller, chief operating officer at Quanterix, highlights neurology and oncology as two ...

In this video interview, Michael Miller, chief operating officer at Quanterix, discusses how the use of biomarkers is ...

In the ongoing Phase II CRDF-004 trial, onvansertib plus standard-of-care showed a 49% confirmed ORR and early PFS benefit in ...

In this video interview, Michael Miller, chief operating officer at Quanterix, discusses how biopharma companies—especially ...

In this video interview, Michael Miller, chief operating officer at Quanterix, outlines key technical and regulatory ...